Georgia's Online Cancer Information Center

Find A Clinical Trial

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Status
Active
Cancer Type
Solid Tumor
Unknown Primary
Trial Phase
Phase I
Phase II
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCT ID
NCT03785249
Protocol IDs
849-001 (primary)
NCI-2019-01032
Study Sponsor
Mirati Therapeutics

Summary

This study will evaluate the safety, tolerability, drug levels, molecular effects, and
clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have
a KRAS G12C mutation.

Objectives

This study will evaluate the safety, tolerability, pharmacokinetics, metabolites,
pharmacodynamics, and clinical activity of MRTX849 (adagrasib) in patients with advanced
solid tumors with a KRAS G12C mutation. MRTX849 (adagrasib) is an orally-available small
molecule inhibitor of KRAS G12C.

Eligibility

  1. Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
  2. Unresectable or metastatic disease
  3. Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
  4. Adequate organ function

Treatment Sites in Georgia

Northside Hospital Cancer Institute


1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.